



## LJMU Research Online

**Gunn, A, Pitt, SJ, Graham, MA, Dedi, CG and Taylor-Harris, PM**

**Antimicrobial properties of mucus from the brown garden snail *Helix aspersa***

<http://researchonline.ljmu.ac.uk/id/eprint/2776/>

### Article

**Citation** (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

**Gunn, A, Pitt, SJ, Graham, MA, Dedi, CG and Taylor-Harris, PM (2015)  
Antimicrobial properties of mucus from the brown garden snail *Helix aspersa*. *British Journal of Biomedical Science*, 72 (4). pp. 174-181. ISSN 0967-4845**

LJMU has developed **LJMU Research Online** for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact [researchonline@ljmu.ac.uk](mailto:researchonline@ljmu.ac.uk)

<http://researchonline.ljmu.ac.uk/>

Antimicrobial properties of mucous from the brown garden snail , *Helix aspersa*

Pitt SJ <sup>1</sup>, Graham, MA <sup>2</sup>, Dedi CG <sup>1</sup>, Taylor-Harris PM <sup>3</sup> and Gunn A <sup>4</sup>

<sup>1</sup>School of Pharmacy and Biomolecular Sciences, University of Brighton; <sup>2</sup> Department of Clinical Biochemistry, Western Sussex Hospitals NHS Trust ; <sup>3</sup> Department of Women's Health, Kings College London ; <sup>4</sup> School of Natural Sciences and Psychology, Liverpool John Moores University

### Abstract

Research into naturally occurring antimicrobial substances has yielded effective treatments. One area of interest is peptides and proteins produced by invertebrates as part of their defence system, including the contents of mollusc mucous. Mucous produced by the African giant land snail, *Achatina fulica* has been reported to contain two proteins with broad spectrum anti-bacterial activity. Mucous from the brown garden snail, *Helix aspersa* appears to have skin regeneration properties. This study sought to investigate the antimicrobial properties of *H.aspersa* mucous.

Mucous was collected from *H.aspersa* snails, diluted in PBS and centrifuged, with the supernatant tested against a wide range of organisms in a disc diffusion antimicrobial assay. This was followed up with comparative experiments involving *A.fulica* , including bacteriophage assays. Mucous from both species of snail was passed through a series of protein size separation columns in order to determine the approximate size of the antimicrobial substance. Electrophoresis was also carried out on the *H.aspersa* mucous.

Results indicated that *H.aspersa* mucous had a strong antibacterial effect against several strains of *Pseudomonas aeruginosa* and a weak effect against *Staphylococcus aureus*. Mucous from *A.fulica* also inhibited the growth of *S.aureus*, but the broad spectrum of activity reported by other workers was not observed. Antimicrobial activity was not caused by bacteriophage. Size separation experiments indicated that the antimicrobial substance(s) in *H.aspersa* were between 30 and 100 kDa. Electrophoresis revealed two proteins in this region – 30-40 kDa and 50-60kDa. These do not correspond with antimicrobial proteins previously reported in *A.fulica*.

This study found one or more novel antimicrobial agents in *H.aspersa* mucous, with a strong effect against *P.aeruginosa* .

Key words: antimicrobial, *Pseudomonas aeruginosa*, *Helix aspersa*, mucous

## Introduction

The discovery of antibiotics in the middle of the 20<sup>th</sup> century significantly decreased the morbidity and mortality associated with infectious diseases. However, the ability of microorganisms to develop resistance to antimicrobial agents has been of concern since the first report of reduced susceptibility to penicillin of *Streptococcus pneumoniae* in 1965 <sup>1</sup>. This has now become a major public health issue, noted by the Chief Medical Officer for England in her 2013 annual report <sup>2</sup> and the subject of a World Health Assembly meeting which developed a global plan of action <sup>3</sup>.

Since many of the first antibiotics were naturally occurring substances, researchers have continued to investigate anecdotal evidence and folklore to find new antimicrobial agents. This has led to the discovery that, for example, a topical preparation of the essential oil 'tea tree' (*Melaleuca alternifolia*) from Australia has antiseptic and anti-inflammatory properties <sup>4</sup>, and that the Chinese herbal remedy qinghaosun (artemisinin) derived from *Artemisia annua* is an effective anti-malarial <sup>5</sup>. Copper, which was advocated by Hippocrates for the treatment of leg ulcers, is microbicidal and therefore has a useful role in infection control when incorporated into frequently touched surfaces in hospitals <sup>6</sup>.

One area of current interest is antimicrobial peptides (AMPs) in invertebrates. These are relatively small ( 5-15 kDa ) molecules which are part of the animal's natural defence system <sup>7</sup> Examples which have been characterised from molluscs include defensins, mytilins, myticins and mytimacins <sup>8,9</sup> . Most of the AMPs described to date are found in the haemolymph of the invertebrate and the literature suggests they have activity against an eclectic mix of microorganisms including bacteria, viruses and protozoa <sup>8</sup>.

A range of internal AMPs have been found in gastropods, but it is also likely that their external secretions would have components affording protection against potential pathogens, in a similar manner to the antimicrobial substances found in the mucous of fish and amphibians <sup>10, 11</sup> . Terrestrial slugs and snails produce mucous which performs a variety of functions, including facilitating movement along the ground, communication and a non-specific, defensive response to physical or chemical irritation <sup>12</sup> .

The antimicrobial properties of the mucous collected from African giant land snails ( *Achatina fulica* ) were first described in the 1980s, by researchers in Japan <sup>13, 14</sup> . These authors reported finding that when mucous was mixed with water and centrifuged, the resulting supernatant exhibited antimicrobial activity in a standard disc diffusion assay <sup>13</sup> . Biochemical investigations of the nature of the active ingredient led to the conclusion that it is a glycoprotein <sup>13</sup> of around 140 - 160,000 Da <sup>14, 15</sup> , which they subsequently named 'Achacin' <sup>15</sup> . They stated that Achacin inhibited the growth of a representative selection of Gram positive and Gram negative bacteria, namely *Staphylococcus aureus*, *Bacillus subtilis*, *Escherichia coli* and *Pseudomonas aeruginosa* <sup>13, 14, 15</sup> . From their investigations of its mode of action, they concluded that Achacin is only effective against actively growing and dividing organisms <sup>15</sup> .

This work does not appear to have been followed up extensively, although Zhong *et al.* <sup>16</sup> found a smaller peptide (9700 Da) in *A.fulica* mucous, which they characterised as an AMP in the mytimacin family and therefore called 'Mytimacin-AF'. This was reported to have antimicrobial activity against *Staphylococcus aureus*, several *Bacillus spp.*, *Klebsiella pneumoniae* and *Candida albicans* <sup>16</sup> , but to be particularly effective in reducing growth of *S.aureus*. The authors did not discuss its possible mode of action or reasons for its selectivity. Similarly, Santana *et al.* <sup>17</sup> tested the *in vitro* activity of neat *A.fulica* mucous against *C.albicans*, *E.coli*, *S.aureus*, *S.epidermidis*, *Fusarium spp.* and *Salmonella spp.*. They reported that it inhibited the growth of *S.aureus* and *S.epidermidis*, but did not mention

the results for the assays using the other organisms. In a separate set of experiments, Santana *et al.*<sup>17</sup> formulated mucous into a wound dressing preparation, which was applied to skin lesions on the backs of rats. They presented histological results suggesting that the *A.fulica* mucous promoted wound healing<sup>17</sup>, but specific antimicrobial activity *in vivo* was not reported.

The brown garden snail, *Helix aspersa* has been used in human medicine since antiquity: Hippocrates recommended snail mucus for the treatment of protocele whilst Pliny stated that snail preparations could be employed in everything from childbirth to nosebleeds<sup>18</sup>. Recently, anecdotal reports of generic skin regeneration properties of the mucous from *H. aspersa* have been explored<sup>19</sup>; this has resulted in the commercial production of a topical preparation<sup>20</sup> which is claimed to have “wound healing” as well as anti-ageing properties. Tsoutsos *et al.*<sup>19</sup> tested the preparation on burns patients and while they noted that a range of opportunistically pathogenic bacteria were isolated from swabs collected from the wounds before treatment, this was not followed up with culture of post treatment specimens. Thus, the specific antimicrobial properties of *H.aspersa* mucous do not appear to have been researched.

Therefore the aim of this study was to investigate the antimicrobial properties of mucous from the common garden snail *Helix aspersa* and to characterise any active ingredient(s) discovered. Since most of the previously published work in this area related to *Achatina fulica*, analysis of mucous from this species of mollusc was also included for comparison.

## Method

### *Snail care and mucous collection*

#### *Helix aspersa*

Twenty snails were collected from the wild and kept indoors in a clear plastic tank (35 x 22 x 14cm) at room temperature (~21°C) and ambient light. They were fed on lettuce leaves, cucumber, carrots and apples and provided with water, along with a source of calcium. The tanks were cleaned weekly. Mucous production was encouraged by taking each individual snail and gently stimulating it with a cotton swab moistened in phosphate buffered saline (PBS). The resulting secretions were collected using 10ml plastic Pasteur pipettes and pooled into one aliquot. The mucous was left to settle at room temperature for 1-2hours before dilution at 1:3 in PBS and centrifugation at 4500rpm for 20 minutes. The supernatant was used in subsequent investigations.

#### *Achatina fulica*

Four captive bred juvenile snails were made available for this study courtesy of Dr Sally Williamson, Liverpool John Moores University. They were maintained under the same conditions as the *H.aspersa* snails, except that the tank was slightly deeper (35 x 22 x 21cm) and their diet was cucumber and butternut squash. Mucous production and collection was carried out in a similar manner to that described above for the garden snails. The mucous was diluted in PBS and processed to obtain supernatant as described above.

### *Initial antimicrobial assay*

Supernatant from the 1:3 diluted *Helix aspersa* mucous was tested against a range of organisms, namely: *Candida albicans* ATCC 10231, *Escherichia coli* NCTC 10385, *Klebsiella pneumoniae* NCTC 11228, *Proteus mirabilis* NCTC 10823, *Pseudomonas aeruginosa* NCIMB 10548, *Pseudomonas aeruginosa*, NCTC 8626, *Staphylococcus aureus* NCTC 10788 and *Streptococcus pyogenes* NCIMB 13285, plus 'in house' isolates of *Acinetobacter* spp. (R4474), *Salmonella abony* and *Serratia marcescens*.

Organisms were grown up overnight in broth cultures of Tryptone Soy Broth (TSB), (Oxoid, Basingstoke, Hampshire, UK) and diluted to between  $10^6$  and  $10^7$  colony forming units (cfu) mL<sup>-1</sup> (verified by viable count). A 100µL aliquot of the bacterial suspension was spread onto an Isosensitest agar (ISA) plate (Oxoid, Basingstoke, Hampshire, UK) and left to dry for 15 minutes. Blood agar - prepared using Blood agar base No. 2 (Oxoid Basingstoke, Hampshire, UK) plus 7% blood - was substituted for ISA in the *Streptococcus pyogenes* assay and Sabouraud Dextrose Agar (SDA) (Oxoid, Basingstoke, Hampshire, UK) was used to test the activity against *C.albicans*. Three sterile paper assay discs (5 mm diameter) were applied to each plate and 50µL of the mucous supernatant was added to two of them, while the third was treated with 50µL PBS as a control. Plates were incubated at 37°C for 18-24 hours before being read. Zones of inhibition were recorded in mm. For most of the organisms tested the assay was performed twice and a mean zone of inhibition was calculated. For the two strains of *P.aeruginosa*, the assay was performed four times, generating eight readings from which the mean was taken.

After analysis of the results from the initial antimicrobial assay, the effect of *H. aspersa* mucous on *Pseudomonas aeruginosa* was investigated in more detail and a third strain, namely *Pseudomonas aeruginosa* NCTC 10662 was included. At this point, the *A. fulica* mucous was introduced into the

study for comparison and both types of mucous were also tested against *Escherichia coli* NCTC 10385, *Staphylococcus aureus* NCTC 10788 and *Candida albicans* ATCC 10231.

### Biochemical analysis

An aliquot of 1:3 diluted *H. aspersa* mucous supernatant was analysed for protein content using the Biuret method. The result was obtained in g/L which was then calculated as mg/mL for the undiluted mucous.

### Size separation assays

Approximately 500µL aliquots of the mucous supernatant were processed in a series of Vivaspin 500 protein size separator columns (Sartorius, Epsom, Surrey, UK) at 1,000 kDa, 100 kDa, 30 kDa and 10 kDa following the manufacturer's instructions – including pre-rinsing in distilled water to remove sodium azide. The resulting filtrate and concentrate were each tested in the antimicrobial assay against the three *P. aeruginosa* strains, *S. aureus*, *E. coli* and *C. albicans*. Each plate was set up with 3 test discs and 1 PBS control. All experiments were repeated at least once (i.e. at least 6 replicates); results were scored qualitatively.

### Electrophoresis

*H. aspersa* mucous was processed through the 1, 000 kDa size separation column and the resulting filtrate was analysed by SDS-PAGE electrophoresis, by adding a 25 µL aliquot ( in duplicate) to a 4-12% gradient NuPAGE Novex Bis-Tris Protein gel (Life Technologies, Paisley, UK). The gel was run in NuPAGE MOPS SDS Running Buffer at 200 V for 50 minutes. The Novex Sharp Pre-stained Protein Standard marker LC5800 (Life Technologies, Paisley, UK) was included in the run. The gel was then stained with 0.25% Coomassie Blue R250 dissolved in 50% methanol, 10% acetic acid for 2 hours and destained overnight in several changes of solution containing 5% methanol, 7.5% acetic acid.



### Bacteriophage screening assay

Aliquots of the 1:3 diluted mucous from *H.aspersa* and *A.fulica* were screened for the presence of bacteriophage using a method modified from that described by Adams <sup>21</sup> and tested against the following organisms: *Candida albicans* ATCC 10231, *Escherichia coli* NCTC 10385, *Klebsiella pneumoniae* NCTC 11228, *Proteus mirabilis* NCTC 10823, *Pseudomonas aeruginosa* NCIMB 10548, *Pseudomonas aeruginosa*, NCTC 8626, *Pseudomonas aeruginosa*, NCTC , *Staphylococcus aureus* NCTC 10788 and *Streptococcus pyogenes* NCIMB 13285, plus 'in house' isolates of *Acinetobacter* spp. (R4474), and *Serratia marcescens*.

For each organism 100µL of an overnight broth culture was spread onto a Tryptone Soya Agar (TSA) plate ( Oxoid, Basingstoke, UK). A 5µL drop of each type of mucous was spotted on the plate, which was allowed to dry before incubating for 24 hours at 37°C. An enrichment culture method was also used, where 100µL of host bacteria and 5µL of mucous were inoculated into 10ml TSB and incubated at 37°C for 18 hours. After this, approximately 1mL was passed through a 0.45µm filter to remove the bacteria and 5µL of the resulting suspension spotted onto fresh bacterial lawns and the plates incubated for 24 hours at 37°C. All plates were examined for any signs of clearing.

### Results

Small (between 500 µL and 1mL), but sufficient quantities of mucous were successfully collected from the *H.aspersa* and the *A.fulica* snails each time experiments were conducted. The viscosity of the mucous varied between batches harvested on different days.

The results of testing the supernatant of the *H.aspersa* mucous after 1:3 dilution in PBS against a range of organisms are shown in Table 1. Clear, measurable zones of inhibition were obtained with

the two *P.aeruginosa* strains (Table 1, Figure 1), but no effect was observed for any of the other microorganisms.

Tables 2a and 2b indicate the outcomes from protein size separation experiments. They show that the antimicrobial activity was found in the filtrate from the 1, 000 kDa column for both types of mucous and against the two organisms where zones of inhibition were observed. For the *H.aspersa* mucous, these results located the protein(s) of interest at between 30 and 100 kDa in size (Table 2a), while the active ingredient in *A.fulica* mucous appeared to be around 100 kDa (Table 2b). When testing *H.aspersa* mucous against the strains of *P.aeruginosa*, clear zones of inhibition were obtained, as illustrated by Figure 2. The activity against *S.aureus* found in both types of mucous became apparent after passing mucous through the 1, 000 kDa, but did not result in clear zones (Figures 3a and 3b).

The total protein content of the *H.aspersa* mucous diluted 1:3 was 1.6 g/L. This was calculated to be 4.8mg/mL protein in neat mucous.

The electrophoresis revealed eight protein bands in the *H.aspersa* mucous, including one between 50 and 60 kDa and one at approximately 35 kDa ( Figure 4). Additional bands were noted at >260, 20, 15, 10, 12 and <10 kDa.

No bacteriophage activity was found in the *H.aspersa* or *A.fulica* mucous against the target organisms tested in either the direct or enrichment assay (Table 3). Although there was some faint clearing observed in the direct assay with *Serratia marcescens*, on further investigative sampling, no active bacteriophage were isolated.

## Discussion

This study has shown that the mucous from the common brown garden snail, *Helix aspersa*, has a demonstrable antimicrobial activity against several strains of *Pseudomonas aeruginosa*. The bacteriophage assay results indicated that this is not an effect caused by bacteriophage in the mucous. Previous studies on the antimicrobial activity of snail mucous have not tested for this, although bacteriophages have recently been shown to adhere to the mucous from a wide of organisms, including humans, thus contributing to the antimicrobial response <sup>22</sup>. While the concentration of the active ingredient(s) was not ascertained, clear and repeatable zones of inhibition were observed when the mucous was diluted in PBS but not subject to any other preparation (Figure 1). The diameter of the assay disc was 5mm, which meant that the specific antimicrobial effect accounted for over 6mm in the recorded zones (Table 1). This effect against *P.aeruginosa* was initially found in the unseparated mucous supernatant and subsequent investigations indicated the active ingredient to be between 30 and 100 kDa. As Table 2a shows, antimicrobial effect was found in the concentrate after the 30 kDa size separation and the filtrate after the 100kDa step. Electrophoresis results confirmed that two proteins were present in *H.aspersa* mucous in this size region – one between 50 and 60 kDa and one approximately 35kDa in size (Figure 4). Resistance by *P.aeruginosa* to currently available antimicrobials is an increasing problem in clinical practice <sup>23</sup>. Therefore this is a significant result, which does not appear to have been reported previously.

In contrast, *A.fulica* mucous was not found to have activity against any of the strains of *P.aeruginosa* included in this study, either in the unseparated form or after any of the size separation processes. This was unexpected, since it contradicts previously reported studies <sup>13,14</sup>, which apparently showed a strong effect against this bacterium. It is not clear why this should be the case, but the present

findings appear to concur with those of Santana *et al.*<sup>17</sup>, who did not report any results from their tests using *P.aeruginosa* ATCC 1024.

During the study, it was discovered that the use of the 1, 000 kDa column was a useful concentration step; the active ingredient(s) were retained and it enhanced the effect of both types of mucous against *S.aureus*. (Tables 2a and 2b; Figures 3a and 3b). By using this processing prior to the antimicrobial assays, it was found that *H. aspersa* mucous also had an inhibitory effect against *Staphylococcus aureus*, although it was less marked (Figure 3a). A similar effect was noted with the *A.fulica* mucous (Table 2b, Figure 3b). The fact that *A.fulica* mucous was found to be active against *S. aureus* does concur with previous work<sup>13, 14, 15, 16, 17</sup>, although none of the other authors report the relatively weak effect found in the present study. However, apart from Santana *et al.*<sup>17</sup>, all describe isolating the active ingredient - i.e. Achacin<sup>13, 14, 15</sup> or Mytimycin-AF<sup>16</sup> - before testing it against the bacteria. Santana *et al.*<sup>17</sup>, seem to have followed a very similar antimicrobial assay method to that employed in the present study, with the exception of their use of Mueller – Hinton agar instead of ISA and wells in the agar instead of discs. They reported that an aliquot of 5µL of *A.fulica* mucous did not inhibit growth of *S. aureus*, but that an effect was noted at 10µL and 20µL<sup>17</sup>. They did not attempt to separate out the protein content or concentrate the mucous in any way, so this supports the idea that the effect is enhanced when more of the active ingredient is available to interact with the bacterium.

The *H.aspersa* mucous was not found to be effective against a range of other bacteria or *Candida albicans*. Initially this finding was rather unexpected, since components of *A.fulica* mucous have previously been reported to inhibit the growth of *E.coli*<sup>15, 16</sup>, a number of *Bacillus* species<sup>13, 16</sup> and *K.pneumoniae*<sup>16</sup> as well as *C.albicans*<sup>16</sup>. Extrapolating from the literature it seemed possible that *H.aspersa* mucous might have a similar broad spectrum of activity, which is why a variety of organisms were tested in the initial antimicrobial assay. However, this study was not able to

reproduce the antimicrobial effect of *A.fulica* mucous against *E.coli*, *C.albicans* or *P.aeruginosa*. It is possible that this discrepancy is due to variations in methodology or the strains of organisms used. However, Santana *et al.* <sup>17</sup> also tested *A.fulica* mucous using a simple method (involving whole mucous rather than particular fractions) against a range of organisms and similarly reported an effect for *Staphylococcus* species only. They used different type culture collection organisms for *E.coli*, *P.aeruginosa* and indeed *S. aureus* to the present study <sup>17</sup>, which shows that strain variation is unlikely to be the explanation. By coincidence, they used the same *C.albicans* (ATCC 10231) and found the same (negative) result. In this study, size separation was used to isolate and concentrate the active ingredient (see below), but no effect was observed when *A.fulica* mucous was tested against *E.coli*, *P. aeruginosa* or *C.albicans* (Table 2b). This all suggests that the finding of a limited activity for *H.aspersa* mucous is likely to be genuine.

The *H.aspersa* mucous contained 4.8 mg/mL protein, which is comparable to the 4mg/mL reported by Iguchi *et al.* <sup>13</sup> in *A.fulica* mucous. The size separation experiments (Table 2a) indicated that there were no proteins of less than 30 kDa active against the microorganisms under test in this study. This size and specificity means that it is unlikely that the antimicrobial activity is associated with lysozymes, which are known to be present in snails and their mucous <sup>24</sup>. Invertebrate lysozymes are usually small proteins with molecular weight of around 15kDa. It also indicates that an antimicrobial compound analogous to Mytimacin-AF <sup>16</sup> or any other AMP <sup>8</sup> is unlikely to be present. In this study, the substance which was active against *S.aureus* in *A.fulica* was present in both the filtrate and the concentrate after separation in the 100 kDa column. This was a surprise, since Achacin is reported to be a protein of 160 kDa, formed of two subunits of 70-80 kDa each <sup>14</sup>. It would be expected that only the whole molecule would be active in the antimicrobial assays and that the effect would therefore have been seen solely in the 100kDa concentrate, but it was not (Table 2b).

Size separation experiments indicated that the antimicrobial effect in the *H.aspersa* mucous was due to one or more proteins of between 30 and 100kDa in size (Table 2a) and electrophoresis revealed no clear band present in 110-160 kDa region (Figure 4). Bands were visible at between 30 and 40 kDa and between 50 and 60 kDa (Figure 4), but they were comparatively faint, suggesting that these proteins were present in relatively low concentrations. It therefore could be that *H.aspersa* mucous does indeed contain an antimicrobial protein which corresponds to Achacin and is of a similar size, but that it is was not detectable by the biochemical methods used in this study. This idea is supported by the fact that mucous from both species of snail produced a similar, albeit relatively weak, antimicrobial effect against *S. aureus* in the assay used here (Figures 3 a and 3 b) and Achacin is reported to be effective in killing this Gram positive coccus <sup>15</sup>. However the ingredient active against *S.aureus* in the *H.aspersa* mucous was clearly within the 30-100 kDa range and it is possible that one of the two proteins identified in this region are responsible for the anti-staphylococcal effect.

The activity of the *H.aspersa* mucous against *P.aeruginosa* appears to be stronger and there are two possible explanations for this. One is that there is an Achacin-like protein and that it interacts differently with the *P.aeruginosa*. This is plausible since Otsuka-Fuchin *et al.* <sup>15</sup> suggested that Achacin could be targeting cell wall synthesis and *P.aeruginosa* is a Gram negative bacillus, with a different cell wall composition to *S.aureus*. Alternatively, since antimicrobial agents exploit peculiarities in prokaryotic metabolism, this protein could be interfering with a species specific pathway. The other possibility is that one or both of the two smaller proteins (30-40 kDa and 50-60kDa in size) identified as potential antimicrobials in *H.aspersa* mucous are affecting the *P.aeruginosa*. The strength of the effect on bacteria of this species (Figures 1a, 1b and 2) could be because the two substances interact to achieve the anti-microbial effect. Further work to fully

characterise the active ingredient(s) and exploration of the specific antimicrobial effects should clarify this

Although the results presented here were repeatable, it was not possible to confirm many of the previously published findings with *A. fulica*. This could be due to the low concentration of the active ingredient(s) in the mucous as it was collected and processed in this study. It is therefore possible that *H. aspersa* has a broader spectrum of activity than found here, analogous to that reported by other authors for *A. fulica*. Once the active ingredient has been fully characterised, tests with the wide range of microorganisms used in initial antimicrobial assay in this study could be repeated.

Further work would include obtaining a profile of the protein content for example using matrix assisted laser desorption/ionisation (MALDI) and then isolating fractions of the mucous protein without denaturing them -using for example high performance liquid chromatography (HPLC) or native gel electrophoresis; the individual fractions could then be put into the antimicrobial assay in order to determine the exact size of the active ingredient(s). Once this was known, the protein could be sequenced and fully characterised which would allow elucidation of its site and mode of action against relevant microorganisms.

In this study, *H. aspersa* mucous was found to be equally effective against three laboratory strains of *P. aeruginosa*. The next phase therefore would be to test it (*in vitro*) against clinical isolates. If this proves successful, then the effectiveness of the topical preparation, such as the one already available commercially <sup>19</sup> could be explored.

The antimicrobial activity in *H. aspersa* mucous appears to be caused by one or more novel substances with molecular weight between 30 and 100 kDa. There is a particularly strong inhibitory effect against *P. aeruginosa* and further investigation is warranted.

Acknowledgements: We would like to thank Mr S Short for supporting MG in this project, Ms R Berterelli, Mrs H Catty and Mr J. Hawthorne for technical support, Ms A Blunden and Ms L Jolliffe for looking after the snails, Dr G Olivier, Dr A Sheerin and Dr N Stewart for advice regarding the biochemistry aspects of this work and Dr S Williamson for the loan of the *A.fulica* snails.

## References

1. Applebaum PC. Antimicrobial Resistance in *Streptococcus pneumoniae*: An Overview. *Clin Infect Dis* 1992; **15**:77-83.
2. Davies SC , Fowler T, Watson, J *et al.* Annual Report of the Chief Medical Officer: infection and the rise of antimicrobial resistance *Lancet* 2013; **381** (9878): 1606-09.
3. Shallcross LJ , Davies SC .The World Health Assembly resolution on antimicrobial resistance *J Antimicrob Chemother* 2014; **69**: 2883-5.
4. Carson CF, Hammer KA, Riley TV . *Melaleuca alternifolia* (Tea Tree) Oil: a Review of Antimicrobial and Other Medicinal Properties. *Clin Microbiol Rev* 2006; **19**: 50-62 .
5. Tu Y. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine *Nature Med* 2011; **17** :1217–20 .
6. O’Gorman J , Humphreys H . Application of copper to prevent and control infection. Where are we now? *J Hosp Infect* 2012; **81**: 217-33
7. Soderhall, K. Invertebrate Immunity. New York: Springer Science & Business Media, 2011.



8. Li H, Parisi, M-G, Parrinello, N, *et al.* Molluscan antimicrobial peptides, a review from activity-based evidences to computer-assisted sequences. *Invertebrate Surviv J*, 2011; **8**: 85-97
9. Gerdol M, de Moro G, Manfrin C, *et al.* (2012). Big defensins and mytimacins, new AMP families of the Mediterranean mussel *Mytilus gallo-provincialis*. *Dev Comp Immunol* 2012; **36**: 390-9.
10. Bergsson G, Agerberth B, Jörnvall J, Gudmundur HG. Isolation and identification of antimicrobial components from the epidermal mucus of Atlantic cod (*Gadus morhua*). *FEBS J* 2005 ; **272**: 4960-9
11. Rollins-Smith LA, Woodhams DC, Reinert LK *et al.* (2006) Antimicrobial peptide defenses of the mountain yellow-legged frog (*Rana muscosa*). *Dev Comp Immunol* 2006; **30**: 831-842.
12. Denny M.W. Invertebrate mucous secretions: functional alternatives to vertebrate paradigms. *Symp Soc Exp Biol* 1989; **43**: 337-6.
13. Iguchi SMM, Takashi A , Matsumoto JJ . Antibacterial activity of snail mucus mucin. *Comp Biochem Physiol A* 1982 ; **72**: 571-4
14. Kubota Y , Watanabe Y, Otsuka H *et al.* Purification and characterization of an antibacterial factor from snail mucus. *Comp Biochem Physiol C* 1985; **82** : 342-8
15. Otsuka-Fuchino H , Watanabe Y, Hirakawa C, *et al.* Bactericidal action of a glycoprotein from the body surface mucus of Giant African Snail *Comp Biochem Physiol C* 1992; **101**: 607-13
16. Zhong J, Wang W, Yang X, *et al.* A novel cysteine-rich antimicrobial peptide from the mucus of the snail of *Achatina fulica*. *Peptides* 2013; **39**: 1-5
17. Santana WA, Melo CM, Cardoso JC *et al.* Assessment of Antimicrobial Activity and Healing Potential of Mucous Secretion of *Achatina fulica* . *Int J Morphol* 2012 ; **30**: 365-73

18. Bonnemain B. *Helix* and drugs : snails for western health care from antiquity to the present. *Evid Based Complement Alternat Med* 2005; **2** : 25-28
19. Tsoutsos D, Kakagia D, Tamparopoulos K . The efficacy of *Helix aspersa* Müller extract in the healing of partial thickness burns: A novel treatment for open burn management protocols. *J Dermatolog Treat* 2009; **20**: 219-22
20. drorganic.co.uk: <http://www.drorganic.co.uk/snail-gel-products.asp> accessed 31/12/14
21. Adams MD. *Bacteriophages*. New York: Interscience Publishers. Inc., 1959
22. Barr JJ, Auro R, Furlan M *et al*. Bacteriophage adhering to mucus provide a non–host-derived immunity. *Proc Natl Acad Sci USA* 2013; **110**: 10771-6.
23. Breidenstein EBM, de la Fuente-Núñez C , Hancock REW. *Pseudomonas aeruginosa*: all roads lead to resistance. *Trends Microbiol* 2011; **19**: 419-26
24. Fiolka MJ, Witkowski A. Lysozyme-like activity in the eggs and some tissues of land snails *Helix aspersa maxima* and *Achatina achatina*. *Folia Biol (Krakow)* 2004; **52**: 233-7.

Table 1: Mean zones of inhibition in antimicrobial assay with 1:3 diluted *H. aspersa* mucous

Organism	Mean zone of Inhibition, mm (SD)	
	PBS control	Mucous supernatant
<i>Staphylococcus aureus</i> NCTC 10788	0	0
<i>Streptococcus pyogenes</i> NCIMB 13285	5.5 <sup>1</sup>	5.5
<i>Candida albicans</i> ATCC 10231	0	0
<i>Escherichia coli</i> NCTC 10385	0	0
<i>Klebsiella pneumonia</i> NCTC 11228	0	0
<i>Salmonella abony</i> <sup>2</sup>	0	0
<i>Proteus mirabilis</i> <sup>2</sup>	0	0
<i>Acinetobacter</i> spp. <sup>2</sup>	0	0
<i>Serratia marcescens</i> <sup>2</sup>	0	0
<i>Pseudomonas aeruginosa</i> 8626	0	11.12 ( 2.57)
<i>Pseudomonas aeruginosa</i> 10548	0	11.63 ( 1.52)

<sup>1</sup> non-specific zone of haemolysis noted in both control and test plates; <sup>2</sup> 'in house' isolates with no type culture collection identification

Table 2a: The effect of passing *H.aspersa* mucous through protein size separator columns on the retention of antimicrobial activity , indicating zone of inhibition ( +) or no zone of inhibition (-).

	10kDa column		30kDa column		100 kDa column		1,000 kDa column	
	Filtrate	Concentrate	Filtrate	Concentrate	Filtrate	Concentrate	Filtrate	Concentrate
<i>E. coli</i> NCTC 10385	-	-	-	-	-	-	-	-
<i>C. albicans</i> ATCC 10231	-	-	-	-	-	-	-	-
<i>S. aureus</i> NCTC 10788	-	+	-	+	+	-	+	-
<i>P.aeruginosa</i> NCTC 8626	-	+	-	+	+	-	+	-
<i>P.aeruginosa</i> NCIMB 10548	-	+	-	+	+	-	+	-
<i>P.aeruginosa</i> NCTC 10662	-	+	-	+	+	-	+	-

In all cases, PBS control discs gave a zone size of 0mm.

Table 2b : The effect of passing *A.fulica* mucous through protein size separator columns on the retention of antimicrobial activity, indicating zone of inhibition ( +) or no zone of inhibition (-).

	10kDa column		100 kDa column		1,000 kDa column	
	Filtrate	Concentrate	Filtrate	Concentrate	Filtrate	Concentrate
<i>E. coli</i> NCTC 10385	-	-	-	-	-	-
<i>C.albicans</i> ATCC 10231	NT	NT	NT	NT	-	-
<i>S.aureus</i> NCTC 10788	-	-	+	+	+	-
<i>P.aeruginosa</i> NCTC 8626	-	-	-	-	-	-
<i>P.aeruginosa</i> NCIMB 10548	-	-	-	-	-	-
<i>P.aeruginosa</i> NCTC 10662	-	-	-	-	-	-

In all cases, PBS control discs gave a zone size of 0mm. ; NT = not tested

Table 3: Results from direct and enriched phage assays against a range of target organisms

Organism	<i>H. aspersa</i> mucous		<i>A. fulica</i> mucous	
	Direct phage assay	Enriched phage assay	Direct phage assay	Enriched phage assay
<i>Pseudomonas aeruginosa</i> NCIMB 10548	No zone	No zone	No zone	No zone
<i>Pseudomonas aeruginosa</i> NCTC 8626	No zone	No zone	No zone	No zone
<i>Pseudomonas aeruginosa</i> NCTC 10662	No zone	No zone	No zone	No zone
<i>Staphylococcus aureus</i> NCTC 10788	No zone	No zone	No zone	No zone
<i>Streptococcus pyogenes</i> NCIMB 13285	No zone	No zone	No zone	No zone
<i>Proteus mirabilis</i> NCTC 10823	No zone	No zone	No zone	No zone
<i>Klebsiella pneumonia</i> NCTC 11228	No zone	No zone	No zone	No zone
<i>Escherichia coli</i> NCTC 10385	No zone	No zone	No zone	No zone
<i>Serratia marcescens</i>	No zone <sup>1</sup>	No zone	No zone	No zone
<i>Acinetobacter</i> R4474	No zone	No zone	No zone	No zone
<i>Candida albicans</i> ATCC 10231	No zone	No zone	No zone	No zone

<sup>1</sup>Some signs of clearing but no plaques were obtained when the zone was isolated.

Figure 1: Zones of inhibition observed after overnight incubation of 50µl *Helix aspersa* mucous (diluted 1:3) on 5mm disc on lawn of 1a *P.aeruginosa* NCIMB10548 and 1b *P.aeruginosa* NCTC8626

Figure 2 Zones of inhibition with *P.aeruginosa* 10548 after testing the filtrate obtained from passing the *H.aspersa* mucous through a 100 kDa column.

Figure 3 Zones observed in the assay using filtrate from 1,000kDa size separation column against *S.aureus* for a) *H.aspersa* mucous and b) *A.fulica* mucous, showing defined ring with growth of organism within it.

Figure 4 Results obtained from SDS-PAGE electrophoresis using the filtrate obtained from passing *H.aspersa* mucous through a 1, 000 kDa size separation column.